LEP-ETU Approval Status
- FDA approved: No
- Brand name: LEP-ETU
- Generic name: Liposome Entrapped Paclitaxel
- Company: Insys Therapeutics, Inc.
- Treatment for: Ovarian Cancer
LEP-ETU (liposome entrapped paclitaxel) is an easy-to-use (ETU) liposomal formulation of paclitaxel (Taxol) in development for the treatment of ovarian cancer.
Development Status and FDA Approval Process for LEP-ETU
|Jan 26, 2015||Insys Therapeutics Receives FDA Orphan Drug Designation for Its Liposomal Encapsulated Paclitaxel for the Treatment of Ovarian Cancer|
|Sep 29, 2005||NeoPharm Announces LEP-ETU Project Update|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.